Reata Pharmaceuticals, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 22.75 million compared to USD 0.762 million a year ago. Net income was USD 193 million compared to net loss of USD 73.56 million a year ago. Basic earnings per share from continuing operations was USD 5.12 compared to basic loss per share from continuing operations of USD 2.02 a year ago. Diluted earnings per share from continuing operations was USD 4.65 compared to diluted loss per share from continuing operations of USD 2.02 a year ago.
For the six months, revenue was USD 22.94 million compared to USD 1.68 million a year ago. Net income was USD 76.88 million compared to net loss of USD 147.4 million a year ago. Basic earnings per share from continuing operations was USD 2.06 compared to basic loss per share from continuing operations of USD 4.04 a year ago. Diluted earnings per share from continuing operations was USD 1.89 compared to diluted loss per share from continuing operations of USD 4.04 a year ago.